Skip to search formSkip to main contentSkip to account menu

GR 138950

Known as: GR-138950, GR138950 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
PurposeThe aim of this study was to investigate and quantify drug movement to the brain via the neuro-olfactory system after… 
2007
2007
It has been shown that vasoconstrictive drugs such as ephedrine derivatives are able to decrease systemic absorption of drugs… 
2004
2004
Glucocorticoids increase blood pressure in utero, but the mechanisms responsible are unclear. This study investigated the… 
2000
2000
1 The effects of cortisol on blood pressure and the circulating components of the renin‐angiotensin system (RAS) were… 
1997
1997
1 The effect of systemic administration of the nitric oxide synthase inhibitor, NG‐nitro‐L‐arginine methyl ester (L‐NAME) on the… 
1997
1997
The effects of maternal administration of either an angiotensin II type 1 (AT1) receptor antagonist (GR138950) or an angiotensin… 
1996
1996
1 The angiotensin AT1 receptor antagonist, GR138950, produces a long‐lasting antihypertensive effect in conscious renal artery… 
1995
1995
The antagonist activity of GR138950 (1-[[3-bromo-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5- benzofuranyl]methyl]-4… 
1994
1994
We have identified GR138950, a potent antagonist of the angiotensin II receptor with high oral bioavailability, as our second…